Remedium Lifecare Enhances R&D and CDMO, Secures ?182.7 Crore Export Deal

Remedium Lifecare Ltd. is focusing on bolstering its Contract Development and Manufacturing Organization (CDMO) services and research & development (R&D) capabilities, aiming to strengthen its global presence, particularly in the UK and Europe. The company received a near 50% subscription of the total issue size, amounting to ? 24.28 crores in the rights issue. The CDMO upgrade will establish a dedicated quality control and testing infrastructure, enabling the facility to serve as a hub for testing incoming raw materials and finished products. The upgrades are tailored to meet customer-specific quality standards while enabling greater flexibility in project execution. The facility’s enhanced capabilities are expected to improve operational efficiency and unlock new opportunities in global markets, particularly in the UK and Europe, where Remedium recently secured a ?182.7 crore multi-year export contract with a leading pharmaceutical distributor. Additionally, Remlife Global PTE Ltd., a Singapore-based subsidiary of Remedium Lifecare, has partnered with green chemistry technology platform JiyaYu Lifesciences to replace animal-origin raw materials in Active Pharmaceutical Ingredient (API) manufacturing.